Johnson & Johnson’s one-shot coronavirus vaccine can actually be two doses, according to the Biden government.
The vaccine, recently submitted for approval to the U.S. Food and Drug Administration (FDA), has been hailed as one of the most effective ways to increase supply and move President Joe Biden towards his goal of 150 million firearms in the U.S. first 100 days of his tenure.
J&J is currently on track to produce 100 million doses of its single vaccine, but is trying to find a way to update immunization in the face of variants.
However, during a Washington Post Live eventAndy Slavitt, White House Senior Advisor on COVID-19 Response, says the company is currently testing the effectiveness of its shot with a booster.
“Johnson & Johnson is currently evaluating the performance of their vaccine with two doses, their own booster,” he told host Jonathan Capehart, a columnist for the newspaper division.
Until the results of this are in, until the FDA has a say – if the vaccine is even approved – there could be a second hiring from Johnson & Johnson. ‘
The news raises concerns that the US may not be able to immunize enough of the population before the more contagious varieties from the UK and South Africa dominate the US.
Johnson & Johnson’s one-shot coronavirus vaccine can actually be two doses, Andy Slavitt, White House senior advisor for the COVID-19 response, said Thursday. Pictured: J&J vaccine bottles against COVID-19, seen at Klerksdorp Hospital as South Africa on February 18
Slavitt (pictured) told Washington Post Live that J&J is testing the effectiveness of its vaccine with a booster and that the single shot may turn into two
The single shot has been hailed as one of the most effective ways to support President Biden’s goal of 150 million doses delivered in 100 days. The US currently vaccinates between 1.6 and 1.7 million people every day
In its large global study, J & J’s vaccine was found to have an infection prevention rate of 66 percent but was only 57 percent effective when tested in South Africa.
It’s unclear if this will delay FDA approval of the vaccine for emergency approval.
If regulators approve the vaccine, it will be the third shot made available to the American public after vaccines were approved by Pfizer Inc / BioNTech SE and Moderna Inc in December.
Unlike the two currently approved vaccines from Pfizer and Moderna, J & J’s do not need to be shipped frozen.
It also doesn’t use new mRNA technology, but instead combines genetic material from the new virus with the genes from the adenovirus – which causes the common cold – to trigger an immune response.
It’s the same technology the company used to create an experimental Ebola vaccine for people in the Democratic Republic of the Congo in late 2019.
Currently, 40.2 million Americans – 12.2% of the population – have received a dose and 15.4 million – 4.6% of the population – are fully immunized
According to Slavitt, states have not used 46% of their vaccine supplies, or 75%, since Biden took office on Jan. 20
According to J & J’s request, regulators need time to analyze the data and an advisory committee needs to meet.
Last month, Dr. Paul Stoffels, Chief Scientific Office of J & J, J & J is on track to launch the vaccine in March.
It remains unclear whether this latest Slavitt reveal will affect the rollout.
The US has reached an agreement to buy 100 million doses of J & J’s vaccine for $ 1 billion and the option to buy an additional 200 million doses.
On Thursday, Dr. Fauci said J&J is still meeting this single-dose goal and confirmed that the company is delivering a two-shot dose.
This costs the vaccine around $ 10 per dose, but the New Jersey drugmaker has promised not to evaluate its vaccines for profit.
For comparison, the US pays $ 19.50 per dose for Pfizer immunization and $ 32 to 37 per dose of Moderna’s shock.
Meanwhile, the jolt developed by AstraZeneca and Oxford University is estimated to cost between $ 3 and $ 4 per dose.
J&J has announced that it will ship 1 billion cans by 2021 with production in the US, Europe, South Africa and India.
President Biden plans to have 150 million shots in the arms of Americans by the end of April, his first 100 days in office
Slavitt told Washington Post Live that states have stopped consuming 46 to 75 percent of their supply since Biden took office.
He added that there are currently enough vaccine purchases to keep every person in the US vaccinated by July, but that doesn’t include the J&J vaccine.
“We will let the FDA make the decision and not accept anything,” said Slavitt.
This includes letting science lead and not letting the White House sideline. ‘